Evidence mapPaperPMID 40760331Full record

ReviewInnere Medizin (Heidelberg, Germany)2025

[Nephrotic syndrome].

Daniela Anne Braun, Hermann-Josef Pavenstädt

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniela Anne BraunMedizinische Klinik D, Universitätsklinikum Münster, Münster, Deutschland.
Hermann-Josef PavenstädtMedizinische Klinik D, Universitätsklinikum Münster, Münster, Deutschland. hermann.pavenstaedt@ukmuenster.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nephrotic syndrome (NS) is characterized by proteinuria > 3.5 g/day, hypoalbuminemia, peripheral edema, and hyperlipidemia. Common primary causes of NS are podocytopathies, such as minimal change nephropathy, focal segmental glomerulosclerosis, and membranous nephropathy. In a subset of patients with primary NS autoantibodies against podocyte antigens can be detected. Diabetes mellitus, amyloidosis, systemic lupus erythematosus, malignancies, infections, and medications are some of the numerous secondary causes of NS. Beside searching for secondary causes, a kidney biopsy is usually performed to define the entity of NS. Complications of NS include venous thrombosis, infections, and the development of acute or chronic kidney disease. Sodium restriction, loop diuretics, statins, possibly anticoagulation, and antiproteinuric therapy are important measure for supportive therapy in NS. In addition, immunosuppressive treatment is often required.

Indexed as

Nephrotic SyndromeHumansImmunosuppressive AgentsImmunosuppressive AgentsAntipodocytic autoantibodiesGlomerulonephritisNephrotic syndrome/edemaPodocytopathyProteinuria

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.